Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low ...

MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.

New study finds potential link between GLP1 agonists and depression, urging further investigation into patient safety.